Dogs with spinal cord injuries may soon benefit from an experimental drug being tested by researchers at UCSF and Texas A&M College of Veterinary Medicine & Biomedical Sciences — work that they hope will one day help people with similar injuries.
January 18, 2012
November 14, 2011
November 01, 2011
An experimental drug called Ocrelizumab has shown promise in a Phase 2 clinical trial involving 220 people with multiple sclerosis (MS), an often debilitating, chronic autoimmune disease that affects an increasing number of people in North America.
October 26, 2011
The widow of the late Sen. Edward M. Kennedy joined a UCSF panel of caregivers and clinicians who recently explored ways of enhancing the quality of life and care of brain cancer patients.
October 24, 2011
A study by researchers at the University of Mississippi Medical Center and UCSF shows that rats given a popularly prescribed antidepressant during development exhibit brain abnormalities and behaviors characteristic of autism spectrum disorders.
October 19, 2011
Premature infants exposed after birth to drugs known as glucocorticoids are at increased risk for having impaired growth of the cerebellum, according to findings from a new UCSF-led study. The cerebellum is a region of the brain associated with balance, motor learning, language and behavior.
October 14, 2011
The only medication currently approved for stroke treatment – tissue plasminogen activator (tPA), which dissolves blood clots – is associated with an increased risk of bleeding in the brain, particularly among patients with hyperglycemia (high blood sugar).
September 21, 2011
Frontotemporal dementia and amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease -- two fatal neurodegenerative disease with distinct symptoms -- are triggered by a common mutation in many cases, according to researchers who say they have identified the mutated gene.
September 20, 2011
UCSF neurologist William Seeley, MD, has been named a 2011 MacArthur Fellow, one of the highest honors bestowed on an individual in the United States.
September 12, 2011
An enzyme that appears to play a role in controlling the brain's response to nicotine and alcohol in mice might be a promising target for a drug that simultaneously would treat nicotine addiction and alcohol abuse in people.